ALK-positive Non-small Cell Lung Cancer Clinical Trial
Official title:
A Phase II, Multicenter, Single-arm Study to Evaluate Safety and Efficacy of Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
The main purpose of the study is to evaluate safety and efficacy of Alkotinib capsule in patients with ALK-positive non-small cell lung cancer previously treated with crizotinib.While exploring the relationship between biomarkers and drug efficacy and safety.
The drug being tested in this study is called alkotinib. Alkotinib has been demonstrated to benefit people with ALK+ NSCLC. The study is a non-control study. The study will enroll approximately 104 participants. All participants will take alkotinib 300mg throughout the study. This multi-center trial will be conducted in China. The overall time to participate in this study is 3 years. Participants will make multiple visits to the site, and 28 days after last dose of study drug for a follow-up assessment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02513667 -
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT04900935 -
Patient-centered, Optimal Integration of Survivorship and Palliative Care
|
N/A | |
| Recruiting |
NCT06361589 -
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
|
||
| Active, not recruiting |
NCT06410040 -
A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
|
||
| Completed |
NCT02336451 -
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
|
Phase 2 |